Reported 1 day ago
Johnson & Johnson (J&J) has announced its intention to acquire Intra-Cellular Therapies, a company that focuses on treatments for central nervous system disorders, as it aims to enhance its portfolio amidst recent challenges. Intra-Cellular's market value has surged to $10 billion, partly due to successful drug trials and settlements, while J&J's market capitalization stands at $342 billion. This acquisition is set to be one of the biggest in biotech within the past year, reflecting a renewed interest in healthcare investments.
Source: YAHOO